Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

Sex hormone antibodies can help identify male and female contributors in forensic samples.

Experts recommend personalized treatment plans for alopecia areata, using corticosteroids and minoxidil for mild cases, and stronger medications for severe cases.

Treatment with biologic agents can significantly improve psoriasis symptoms, and blood biomarkers could potentially predict individual patient's response to treatment.

Blood tests confirmed a baby in the womb had a CMV infection.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

Arg1+ macrophages may play a role in Alopecia Areata, offering new treatment targets.

Some people with a history of autoimmune hair loss experienced worsening symptoms after COVID-19 vaccination.

Cryotherapy with precise temperature control is a promising treatment for alopecia areata.

Injecting anti-herpes antibodies locally can prevent skin lesions and sweating problems caused by herpes simplex virus in mice.

Propylthiouracil, a thyroid medication, can cause skin blood clots and immune-related blood vessel inflammation.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Higher CRBP1 levels are linked to more severe alopecia areata.

Targeting specific T cells may help treat alopecia areata.

New treatments for alopecia areata, like JAK inhibitors and immunomodulators, are promising.

iNKT cells can help prevent and treat alopecia areata by promoting hair regrowth.

Epigenetic changes in blood cells may contribute to alopecia areata.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

Higher levels of IL-17A and IL-2 are linked to alopecia areata.

Most patients with autoimmune blistering diseases experienced some hair loss, which may be underreported and linked to disease severity.

Alopecia areata involves persistent gene abnormalities and immune activity, even in regrown hair, suggesting a risk of relapse.

AHST shows promise for treating type 1 diabetes but needs more research before widespread use.

Alopecia areata needs new treatments targeting autoimmune processes due to its emotional impact and variable treatment responses.

Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.

Alopecia areata patients have fewer protective regulatory B cells, which may contribute to the disease.

People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.

Tacrolimus treatment for autoimmune hepatitis can cause hair loss.

Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.

Sintilimab treatment caused hair loss but led to complete tumor remission.

CD80CD86 deficiency causes hair loss by disrupting regulatory T cells.